Piramal Pharma (PPL) is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operates under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (PCH) business, selling well-known OTC brands. 

Business area of the company

The company is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global distribution network in various countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the- counter products. 

Businesses of the company

Piramal Pharma Solutions: Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. PPS serves customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables PPS to offer a comprehensive range of services, including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.

Piramal Critical Care: Piramal Critical Care (PCC), a business division of Piramal Pharma, is one of the leaders in inhaled anesthetics and a global player in hospital generics. PCC is motivated by its vision of commitment to delivering critical care solutions for patients and healthcare providers across the globe, while achieving sustainable and profitable growth for all the stakeholders.

Piramal Consumer Healthcare: Piramal Consumer Healthcare (PCH) is one of the fastest-growing businesses of Piramal Pharma. It is among the leading players in the Indian self-care space, with established brands like Littles, Lacto Calamine, i-pill, Tetmosol. Polycrol and Tri-Activ, among others, in the Indian Consumer Healthcare market. The PCH portfolio consists of branded consumer healthcare and wellness products, primarily in areas of routine health disruption and proactive care, expanding across key over the counter (OTC) categories such as Analgesics, Gastro-Intestinal, Hygiene, Skincare, Vitamins and Supplements, Women Care, Baby Care and Kids’ wellness.

Awards and recognition

• 2019: Piramal Pharma honoured with 2019 Global Customer Service Leadership award by Frost & Sullivan.
• 2020: Piramal Pharma Solution received 'Manufacturing Supply Chain Operational Excellence – Pharmaceuticals' award at 7th and 9th Edition of Manufacturing Supply Chain Awards.
• 2020: Piramal Pharma Solutions was recognised as the 'Best Contract Manufacturing (CMO) Provider' at the 7th Annual World ADC Awards.
• 2021: Piramal Pharma Solutions was awarded the ‘2021 Global Contract Development and Manufacturing Organisation Customer Value Leadership Award’ by Frost & Sullivan at the 2021 MEASA Best Practices Awards.
• 2022: Piramal Pharma Ltd-Consumer Products Division was certified by Great Place to Work® Institute, India.
• 2022: Piramal Pharma Ltd - Consumer Products Division was awarded Best Sales Automation (in CPG) by Bizom.
• 2023: Piramal Pharma Solutions retains No. 1 position in Indian Bioservices Industry.
• 2024: Piramal Pharma Solutions Receives the 2024 CDMO Leadership Award.
• 2025: Piramal Pharma Solutions Wins Outsourced Pharma's CDMO Leadership 2025 Award.

Milestones

• 1988: Acquired Nicholas Laboratories, marking entry into pharmaceuticals.
• 1991: Commissioned first formulation plant in Pithampur, Madhya Pradesh, expanding operations in 1992.
• 1992: Renamed Nicholas Laboratories Ltd. to Nicholas Piramal India Ltd.
• 1993: Entered into a joint venture with Allergan, a leader in ophthalmic products.
• 1993: Acquired Roche India’s domestic formulations and nutrition products/ services business.
• 1994: Acquired Boehringer Mannheim's formulation plant in Mahad.
• 1995: Acquired the bulk drug division of Sumitra Pharmaceutical and Chemical Ltd., Hyderabad.
• 1996: Boehringer Mannheim fully acquired.
• 2000: Began collaborative research in gene technology with the Centre for Biochemical Technology.
• 2002: Acquired ICI Pharma.
• 2003: Acquired Global Bulk Drugs.
• 2005: Acquired Avecia Pharmaceuticals.
• 2006: Acquired Morpeth facility from Pfizer.
• 2009: Greenfield investment in Ahmedabad (PPDS).
• 2011: Acquired Oxygen Bio Research, a CRO based in Ahmedabad.
• 2012: Piramal Healthcare renamed to Piramal Enterprises, integrating pharma, Financial Services (FS), and new businesses created / acquired – FS and DRG.
• 2015: Acquired Kentucky-based CDMO Coldstream Laboratories Inc.
• 2016: Acquired Ash Stevens Inc., a U.S.-based developer specializing in high-potency APIs.
• 2020: Acquired solid oral dosage drug product facility in Sellersville, Pennsylvania, from G&W Laboratories Inc.
• 2020: Becomes a subsidiary of Piramal Enterprises and receives strategic growth investment by Carlyle.
• 2021: Acquired Hemmo Pharmaceuticals, a leading Indian manufacturer of peptide APIs.
• 2021 Acquired a minority stake in Yapan Bio, an Indian CDMO specializing in biologics and vaccines.
• 2022: NCLT approves Piramal Enterprises demerger and Piramal Pharma Limited lists on BSE and NSE.
• 2022: Opens a new state-of-the-art API manufacturing facility in Aurora, Canada.
• 2023: Opens a new state-of-the-art API manufacturing facility in Riverview, Michigan.
• 2023: Opens its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
• 2024: PPL forays into men’s grooming market in India with the launch of BOHEM.
• 2024: Piramal Pharma’s GHG Commitment Validated and Approved by SBTi.
• 2024: Capacity Expansion at Piramal Pharma Solutions’ Facility at Lexington, Kentucky.
• 2024: Piramal Pharma ropes in Mrunal Thakur as its brand ambassador for Lacto Calamine.
• 2025: Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts.
• 2025: Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP.
• 2025: Piramal Pharma ropes in Yami Gautam as its brand ambassador for Brand,Little’s.
• 2025: Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility.
• 2025: Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities.
• 2026: Piramal Pharma Limited’s Consumer Healthcare launches Little’s AquaSense Baby Wipes - 99.9% Water.
• 2026: Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities.
• 2026: Piramal Consumer Healthcare’s Tetmosol Announces Pankaj Tripathi as Brand Ambassador; Launches New Campaign and Expands Portfolio.